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Targeting the Receptor for Advanced Glycation Endproducts (RAGE):
A Medicinal Chemistry Perspective
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Division of Imaging Sciences and Biomedical Engineering, King’s College London, King’s Health Partners, St. Thomas’ Hospital,
London, SE1 7EH, United Kingdom
ABSTRACT: The receptor for advanced glycation endproducts (RAGE) is an
ubiquitous, transmembrane, immunoglobulin-like receptor that exists in
multiple isoforms and binds to a diverse range of endogenous extracellular
ligands and intracellular eﬀectors. Ligand binding at the extracellular domain of
RAGE initiates a complex intracellular signaling cascade, resulting in the
production of reactive oxygen species (ROS), immunoinﬂammatory eﬀects,
cellular proliferation, or apoptosis with concomitant upregulation of RAGE
itself. To date, research has mainly focused on the correlation between RAGE
activity and pathological conditions, such as cancer, diabetes, cardiovascular
diseases, and neurodegeneration. Because RAGE plays a role in many
pathological disorders, it has become an attractive target for the development
of inhibitors at the extracellular and intracellular domains. This review describes
the role of endogenous RAGE ligands/eﬀectors in normo- and pathophysio-
logical processes, summarizes the current status of exogenous small-molecule inhibitors of RAGE and concludes by identifying
key strategies for future therapeutic intervention.
■ INTRODUCTION
Advanced glycation endproducts (AGEs) are produced by the
nonenzymatic glycation of proteins upon exposure to reducing
sugars.1 Glycation leads to loss of enzymatic function, protein
cross-linking, or aggregation.2,3 The accumulation of AGEs play
an important role in many health disorders including diabetes
mellitus, immunoinﬂammation, cardiovascular, and neuro-
degenerative diseases.4−9 AGEs mediate their pathological
eﬀects by activating signaling cascades via the receptor for
advanced glycation end products (RAGE), a 45 kDa trans-
membrane receptor of the immunoglobulin superfamily
prevalent at low concentrations in a variety of healthy human
tissues, including the lungs, kidneys, liver, cardiovascular,
nervous, and immune systems.10,11
As a receptor for AGE and other proinﬂammatory ligands,
RAGE has been investigated as a potential biomarker of
numerous pathological conditions. Altered plasma or tissue
level of various RAGE isoforms has been identiﬁed in patients
with diabetic complications, cardiovascular diseases, and
Alzheimer’s disease.12−14 In vitro and in vivo studies have
demonstrated the potential of RAGE as a therapeutic target in
cancer, cardiovascular diseases, and neurodegenera-
tion.7−9,15−17 Our review aims to summarize the knowledge
pertaining to RAGE structure, isoforms, endogenous ligands,
biological functions, and key inhibitor candidates, including
those currently undergoing preclinical and clinical evalua-
tion.17−19
■ STRUCTURE OF RAGE
The full-length human RAGE consists of an extracellular
(amino acid residues 23−342, Figure 1A), hydrophobic
transmembrane (residues 343−363), and cytoplasmic domains
(residues 364−404).20 The extracellular structure of RAGE can
be further subdivided into three immunoglobulin-like domains:
a variable (V) domain (residues 23−116) and two constant C1
(residues 124−221) and C2 (residues 227−317) domains
(Figure 1A).10,20−22 The structure of the V domain consists of
eight strands (A′, B, C, C′, D, E, F, and G) connected by six
loops forming two β-sheets linked by a disulﬁde bridge between
Cys38 (strand B) and Cys99 (strand F).21,22 The C1 domain
folds into a classical C-type Ig domain.21,22 The molecular
surface of V and C1 domains is covered by a hydrophobic
cavity and large positively charged areas. Several hydrogen
bonds and hydrophobic interactions occur between the V and
C1 domains forming an integrated structural unit.21−24 X-ray
crystallography, NMR spectroscopy, and in vitro and in vivo
studies have demonstrated that the joint VC1 ectodomain is
implicated in the interaction with a diverse range of RAGE
ligands of acidic (negatively charged) character, such as AGEs,
S100/calgranulin family proteins, high mobility group box 1
(HMGB1), and β amyloid (Aβ).22−27 In addition, RAGE may
undergo a ligand-driven multimodal dimerization or oligome-
rization mediated through self-association of V−V or C1−C1
domains.21,23,28−30 The stability of this diverse oligomerized
VC1−ligand complex might provide an explanation for its
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aﬃnity/speciﬁcity for a wide-range of protein ligands and the
resulting signal transduction.21,23,28−31
In contrast to the VC1 complex, data from proteolysis,
colorimetry, circular dichroism, and NMR experiments have
described C2 as an independent structural unit ﬂexibly
connected to C1 via a 12-residue-long linker.24 In analogy to
the V domain, X-ray diﬀraction and NMR solution studies
conﬁrm that C2 exists as two-β sheets consisting of eight
strands (A, A′, B, C, E, F, G, and G′) stabilized by disulﬁde
bridges between strands B and F.21 However, the C2 structure
also appears to include a large negatively charged surface with
acidic residues directed toward the basic surface of the VC1
oligomer.21
The extracellular domain (VC1C2) of human RAGE
(UniProtKB Q15109) shares a sequence identity of 79.6%,
79.2%, and 96.5% with mice (Q62151), rats (Q63495), and
primates (Rhesus macaque; F1ABQ1), respectively.32 The
positively charged residues involved in the binding of AGE to
RAGE, including Lys52, Arg98, and Lys110, are conserved in
all four species suggesting a common binding pattern.22,26,28
Little is known about the transmembrane domain of RAGE,
a helical structure containing a “GxxxG” motif, which may
promote the helix−helix homodimerization of the receptor and
thus may be involved in signal transduction.21 Sequence
alignment and superimposition of the NMR-derived C-terminal
of human RAGE with that of glycerol phosphate dehydrogen-
ase GlpA structures, known to form a transmembrane helix
dimer, shows a possible interaction between two GxxxG motifs
involved in RAGE transmembrane helix homodimerization.21
The cytoplasmic tail of RAGE (364−404, Figure 1A)
consists of 42 amino acids. This region is further divided into
at least three parts: a membrane-proximal 17 amino acid
domain rich in basic amino acids (Arg366, Arg368, Arg369, and
Glu371), a central 17 amino acid domain containing glutamic
acids and a phosphorylation site at Ser391 and an unstructured
C-terminus.33,34 NMR titration and in vitro binding studies
have demonstrated that both structural regions are crucial for
the interaction of the RAGE cytoplasmic domain with
downstream eﬀector molecules, including diaphanous-related
formin 1 (DIAPH1), Toll-interleukin 1 receptor domain
containing adaptor protein (TIRAP), and the extracellular
signal-regulated kinase 1 and 2 (ERK 1/2). This results in
downstream activation of the nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB) via the mitogen-activated
protein kinase (MAPK) pathway.34−37 Because the RAGE
cytoplasmic domain plays a signiﬁcant mechanistic role in
RAGE-induced signaling, truncation of this domain abolishes
downstream RAGE activity, and decreases the associated
pathological eﬀects both in vitro and in vivo.38,39 The RAGE
cytoplasmic domain of human RAGE shares a high sequence
identity with primates (92%) and rodents (70.7%).32
■ RAGE ISOFORMS
Because of extensive alternative splicing and metalloprotease-
mediated cleavage, RAGE coexists as multiple transcript
variants with diﬀering ligand binding properties and diverse
biological functions.40,41 In addition, a number of RAGE
polymorphisms have been reported as potential disease
biomarkers in human subjects.42,43 RAGE isoforms include
the full-length RAGE, dominant negative RAGE (DN-RAGE,
residues 23−363), N-truncated RAGE (N-RAGE, 124−404),
and C-truncated secretory/soluble RAGE (sRAGE, 23−
342).44,45
The full-length RAGE (Figure 1B) contains all key receptor
components and represents its active form to transduce the
intracellular signal. RAGE binds numerous ligands and acts as a
Figure 1. (A) Structure of full-length RAGE, including the variable (V) domain, constant (C1 and C2) domains, the transmembrane region, and the
cytoplasmic tail. A disulﬁde bridge between Cys38 (strand B) and Cys99 (strand F) links the two β-sheets of the V domain. (B) RAGE isoforms.
The key RAGE isoforms in the illustration include (from the left) the full-length RAGE, oligomerized full-length RAGE, dominant negative RAGE
(DN-RAGE), N-truncated RAGE (N-RAGE), and soluble (secretory) RAGE (sRAGE). (C) The summary of extracellular ligands, intracellular
eﬀectors, and inhibitors binding to RAGE.
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key mediator in several downstream signaling cascades aﬀecting
immunoinﬂammatory responses, oxidative stress levels, cellular
migration, proliferation, and apoptosis.17,25,37,40,46 These eﬀects
are likely to be potentiated by a positive feedback loop whereby
initial RAGE activation leads to increased RAGE expres-
sion.47−52
The absence of the cytoplasmic domain in DN-RAGE
(Figure 1B) produces a “dominant negative” eﬀect with a
blunted signal transduction response to RAGE ligands.48,53
Overexpression of DN-RAGE attenuated HT1080 human
ﬁbrosarcoma cell proliferation and invasion in vitro and
tumorigenesis in vivo.48
The N-truncated isoform of RAGE (N-RAGE, Figure 1B)
lacking the N-terminal V domain is incapable of interacting
with AGEs because the V-domain is critical for their binding.
However, the activation of N-RAGE might produce patho-
logical eﬀects through a pathway independent of the V-
domain.54
sRAGE (Figure 1B) is the circulating soluble form of RAGE
which lacks the transmembrane and cytoplasmic domains.
sRAGE consists of a heterogeneous population, comprising
both isoforms generated from RAGE pre-mRNA alternative
splicing (esRAGE) and the cleavage of RAGE extracellular
domain from the cell surface receptor via matrix metal-
loproteinases.55 sRAGE is the dominant form of the receptor
counteracting RAGE-mediated pathogenesis by acting as a
decoy.11,13,14,56 Translational human studies of pathological
states, such as cardiovascular disorders or Alzheimer’s disease
(AD), demonstrated their association with decreased blood
plasma levels of sRAGE.13,14 The sequestering activity of
sRAGE prevents ligand binding to RAGE, moderating the
positive feedback-driven pathophysiological signaling path-
way.57,58 The administration of sRAGE either peripherally or
directly to target organs has been shown to reverse some of the
RAGE-mediated pathological eﬀects in vivo.47,56,58−60
■ EXTRACELLULAR RAGE LIGANDS
Because of the presence of multiple domains (V, C1, and C2),
receptor isoforms, and polymorphisms, RAGE is able to
interact with a series of diﬀerent ligands: from relatively low
molecular weight AGEs, such as Nε-carboxy-methyl-lysine
(CML), Nε-carboxy-ethyl-lysine (CEL), and methylglyoxal-
derived hydroimidazolones (MG-H) to larger structures
including Aβ (Aβ1−40 and Aβ1−42) and proteins such as
HMGB1, S100/calgranulins, Aβ ﬁbrils, and cross-linked/
modiﬁed Aβ (Figure 1C, Table 1).17,23,26,61−63 With its ability
to bind such a diverse group of molecules, RAGE resembles a
pattern recognition receptor, such as Toll-like receptors (TLR),
Table 1. Intracellular Ligands Binding to RAGE
ligand RAGE isoform
RAGE binding
domain aﬃnity for RAGE (Kd) binding assay
CML/CEL modiﬁed
peptidesa
human sRAGE V 90−100 μM ﬂuorescence titration22
NMR titration28
MG-Hb human sRAGE V 30−40 nM ﬂuorescence titration26
S100Bc human sRAGE VC1 3.2−9.4 μM ITC
VC1 Kd1 = 11 nM, Kd2 = 244 nM SPR
24
V Kd1 = 550 nM, Kd2 = 470 nM
VC1 Kd1 = 11 nM, Kd2 = 200 nM SPR
72
V Kd1 = 0.5 μM, Kd2 = 0.6 μM
V Kd = 8.3 μM (S100B dimer), Kd1 = 1.1 μM, Kd2 = 42 nM
(S100B tetramer)
SPR62
S100P human RAGE V 6 μM ITC and ﬂuorescence
spectroscopy77
S100A6d human sRAGE VC1 0.6−5.8 μM SPR72
V 0.5−13.5 μM
C2 28 nM to 1 μM
S100A12 human sRAGE C1 70 nM ﬂuorescence titration29
HMGB1 (amphoterin) rat and mouse
sRAGE
VC1C2 6−10 nM in vitro saturation binding
assay27
β amyloide human sRAGE V 70−80 nM in vitro saturation binding
assay17
quinolinic acidf human and rat
sRAGE
VC1 43 nM ﬂuorescence titration87
aNMR structure of CEL-modiﬁed peptide with RAGE V domain reported in ref 22 (PDB 2L7U). bNMR complex of MG-H1 and RAGE V domain
reported in ref 26. cNMR and docking calculation of S100B with RAGE VC1 domain reported in ref 23. dNMR (PDB 2M1K, ref 141) and X-ray
(PDBs 4YBH and 4P2Y, ref 142) structures of S100A6 in complex with RAGE V and VC1C2 domains, respectively. eRAGE-Aβ model complex
predicted by protein−protein docking software reported in ref 83. fBinding mode of quinolinic acid and RAGE VC1 domain predicted by
computational docking in ref 87.
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which are expressed on the cells of the innate immune system
(e.g., macrophages) and are involved in the recognition of
antigens presented by various pathogens.28,64 However, in
contrast to TLR, RAGE ligands are of endogenous origin and
typically accumulate in tissues during aging, inﬂammation, or in
response to other tissue stresses.26,47,65−68
CML and CEL. CML and CEL are two common
endogenous AGEs found in humans which bind to the V
domain of RAGE to trigger an immunoinﬂammatory
response.1,22 In clinical studies of diabetes mellitus, high
blood plasma levels of CML have been associated with
enhanced RAGE expression.69 Acidic peptide-bound CML
and CEL appear to interact with positively charged (Lys52,
Lys110, and Arg98) and hydrophobic residues of RAGE V
domain (Table 1).22,28 However, NMR studies have shown that
CML and CEL can only bind to RAGE if they are incorporated
into larger peptide structures.22,28 The binding aﬃnities (Kd) of
such CML or CEL-containing peptides for the V domain of
RAGE are reported to be around 100 μM with little
dependence on the peptide chain modiﬁcation (Table 1).22,28
MG-H. An increased prevalence of methylglyoxal (MG) in
vitro and in vivo has been linked to diabetic vascular
complications with concomitant RAGE overexpression.70
The NMR structural elucidation of an MG derivative (MG-
H1) and RAGE reveals that MG-H1 forms charge−dipole and
dipole−dipole interactions with the V domain (Figure 1C).26
This binding begins a sustained period of cellular activation
mediated by RAGE-dependent signaling such as increased
phosphorylation of c-Jun N-terminal kinase (JNK) in vitro.26
However, in contrast to CML or CEL, MG-H1 does not
require an attachment to a peptide carrier to exert the eﬀect and
binds to RAGE with nanomolar aﬃnity (Kd = 40 nM, Table
1).26 The imidazolone ring is found to be key to the interaction
between MG-H analogues and residues on the V domain,
particularly Lys52, Arg98, and Lys110, which are also involved
in RAGE binding by CML/CEL.22,28
S100/Calgranulin Family of Proteins. The S100/
calgranulin family is a diverse group of Ca2+-binding functional
proteins involved in apoptosis, cell proliferation, diﬀerentiation,
and immunoinﬂammatory response, showing varying aﬃnities
for diﬀerent RAGE domains and triggering distinct cellular
signaling pathways.71−73 S100B is a well-studied member of the
family, which may act as a cytokine and has been implicated in
both neurodegeneration and carcinogenesis.65,66 S100B exists
as homo- or heterodimers with each subunit composed of two
EF hand (helix−loop−helix) motifs.61,62 The binding of S100B
to RAGE resembles that of AGEs because it docks around the
positively charged surface of the VC1 domain, reﬂecting the
acidic character of the ligand.23,72 The activation of RAGE
signaling pathways by S100B is inhibited by sRAGE pretreat-
ment.74
Park and colleagues demonstrated that recognition of S100B
by RAGE occurs via an entropically mediated process involving
a Ca2+-dependent hydrophobic interaction with the RAGE
extracellular V and C1 domains.61 It has been demonstrated
that S100B binding is highly inﬂuenced by the Ca2+-dependent
conformational change of the ligand, which undergoes
oligomerization into hexamer or octamer complexes with
Ca2+ in the human brain.61,62 Isothermal titration colorimetry
(ITC) experiments showed that S100B recognizes RAGE by a
Ca2+ ions dependent process.61 The measured binding aﬃnity
of S100B for sRAGE is inﬂuenced by its degree of
oligomerization and the RAGE construct used in the assay.61
The Kd values of S100B for the V and VC1 domains of
immobilized sRAGE are 0.5 μM and 11 nM, respectively
(Table 1).24,72 A greater level of oligomerization (S100B
tetramer versus S100B dimer) appears to generally improve the
S100B binding aﬃnity for RAGE and favors cell growth.61
The interaction between S100B−Ca2+ complex and RAGE
homodimers also induces receptor oligomerization.75 As
recently demonstrated by Xue et al., this S100B-driven
sRAGE oligomerization may in turn accommodate the
interaction between RAGE and its intracellular eﬀector proteins
(e.g., DIAPH1), thereby initiating a downstream signaling
pathway.75
In analogy to S100B, S100P binds to the RAGE V domain
and activates various signaling pathways (e.g., ERK, MEK,
MAPK, and NF-kB) to promote tumor growth and meta-
stasis.76−78 The Ca2+-bound S100P homodimer interacts RAGE
V domain with moderately strong aﬃnity (Kd = 6.0 μM, Table
1), resulting in RAGE homodimerization.77 The binding
interface of RAGE and S1000P overlaps with the region
involved in S100B and AGEs interaction.23,77,79
Calgranulin C (S100A12) is yet another cytokine-like
member of the S100 family that, like S100B, binds Ca2+
forming dimers or hexamers, enabling a conformational change
and leads to the ligation of RAGE through two hydrophobic
surfaces.29 However, in contrast to S100B, the ﬂuorescence
titrations and NMR spectra compiled by Xie et al. showed that
the interaction between S100A12 and sRAGE occurs through
the C1 domain without a signiﬁcant involvement of either the
V or C2 domains.29
While binding to VC1 is favored by the majority of S100
ligands (e.g., S100B), surface plasmon resonance (SPR) and in
vitro studies by Leclerc and colleagues show a preferential
ligation of S100A6 for C2 compared with VC1.71,72 The
binding of S100B and S100A6 to RAGE is also associated with
two distinct eﬀects on the downstream signaling pathway and
opposite physiological eﬀects in neuroblastoma cells.72 While
both ligands increase the production of ROS, S100B binding to
RAGE activates protein kinase B (AKT), the NF-κB pathway,
and increases cell proliferation, whereas S100A6 binding
induces the JNK/caspase 3 and 7 pathway, resulting in
enhanced apoptosis.72
HMGB1 (Amphoterin). HMGB1 is a “cytokine-type”
RAGE ligand, produced by monocytes, that plays a role in
inﬂammation, regulation of cell migration, and angiogenesis in
vitro and potentially aﬀects development of metastatic
malignant disease in vivo.63,67,68 In addition to activating
RAGE signaling, HMGB1 facilitates its inﬂammatory eﬀects by
binding to other pattern recognition receptors, such as TLR4 in
macrophages, thus conﬁrming the similarity between RAGE
and TLRs.80 Some of the HMGB1 activities may be mediated
through its function as a binding enhancer between RAGE and
other ligands (e.g., macrophage adhesion ligand-1).81 Similarly
to S100B, HMGB1 is likely to form a helix−loop−helix
structure and utilizes its acidity to ligate RAGE via the C-
terminal.62,63 The RAGE-binding region on HMGB1 appears
to lie between residues 150 and 183 with an in vitro Kd in the
low nanomolar range (Table 1).27,63
Beta Amyloid. An increasing number of studies describe
the interaction between RAGE and various forms of Aβ,
particularly Aβ1−40 and Aβ1−42 peptides, leading to neuro-
degeneration and cognitive decline.17,19,46,82 A molecular model
of the dimeric Aβ and V domain of RAGE proposes the
formation of ionic interactions between the acidic negatively
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charged surface of Aβ and the positively charged residues of the
V domain.83 The binding aﬃnity of soluble Aβ to RAGE is
concentration-dependent, with a Kd for
125I-labeled Aβ1−40 of
75 nM.17 A mouse transgenic model of AD showed that Aβ
binds to RAGE, resulting in transport of Aβ from the
bloodstream across the blood−brain barrier (BBB) and into
the central nervous system (CNS) while RAGE inhibition
suppresses the accumulation of Aβ in the brain.84 The
interaction of Aβ with RAGE in neuronal and endothelial
cells induces oxidative stress and activates NF-κB.85
Moreover diﬀerent Aβ conformational states, Aβ oligomers,
ﬁbrils, and aggregates interact in distinct RAGE binding sites.25
In cell assays, oligomers and aggregates induce apoptosis
through RAGE by activating caspase signaling and DNA
fragmentation. RAGE-mediated Aβ oligomer- and aggregate-
induced apoptosis requires the speciﬁc antagonism of the V and
C1 domain of RAGE, respectively.25
Quinolinic Acid. Quinolinic acid, a neuroactive metabolite
of the kynurenine pathway, produces its neurotoxicity by
overactivating the NMDA receptor, causing energy deﬁcits,
oxidative stress, and cell death.86 The excess of quinolinic acid
has been implicated in the development of various neuro-
degenerative disorders such as AD and Huntington’s disease.86
More recently, quinolinic acid has been investigated as a
putative endogenous RAGE ligand.87,88 Flexible docking studies
with quinolinic acid on human and rat VC1 domains by
Serratos and co-workers identiﬁed the binding pattern across
seven sites, including the CML/CEL and MG-H binding
loci.22,26,87 Using ﬂuorometric measurements, the Kd of
quinolinic acid for VC1 was estimated to be approximately
43 nM (Table 1).87 The eﬀects of in vivo administration of
quinolinic acid to rats activated the RAGE pathway, producing
increased levels of oxidative stress, lactate dehydrogenase, and
nitric oxide, enhanced expression of RAGE, COX-2, and NF-
κB, and led to dose-dependent neuronal death in the
striatum.87,88
■ INTRACELLULAR RAGE EFFECTORS
Despite the focus on the VC1 ectodomain of RAGE as the
primary ligation site, the cytoplasmic domain of RAGE is
essential for RAGE-mediated signaling and overall RAGE
function. Recent reports employed a more holistic approach of
evaluating the protein eﬀector interactions encountered by the
cytoplasmic domain of RAGE, including DIAPH1, ERK 1/2,
TIRAP, and dedicator of cytokinesis 7 (DOCK7).33−35,37,89
While in vitro-focused research to date has demonstrated the
necessity of RAGE cytoplasmic tail binding to its intracellular
adaptor proteins in order to facilitate the downstream signaling
cascade, little is known about the speciﬁc binding sites of such
molecules or the aﬃnity at which this binding occurs. Future
studies may therefore beneﬁt the ﬁeld by exploring the docking
patterns and aﬃnity of molecules for ERK, TIRAP, and
DOCK7 in order to explore them as potential targets for
therapeutic intervention.
DIAPH1. DIAPH1 is one of the proteins that binds to the
cytoplasmic tail of RAGE and has proven essential for RAGE-
induced downstream signaling.35,37 Because DIAPH1 is also
involved in actin and microtubule polymerization, it may play a
direct role in tumor growth and its metastatic potential.90 As
could be anticipated, inhibition of RAGE−DIAPH1 complex
formation successfully reduces the ligand-binding (e.g., CML)
induced eﬀects in vitro and in vivo.34,35 This demonstrates the
importance of such protein−protein interactions in down-
stream signaling cascades (e.g., ERK and AKT pathways), cell
migration and division, production of inﬂammatory cytokines
(e.g., TNF-α), and direct myocardial ischemia.34,35 Solution
NMR spectroscopy and site-directed mutagenesis identiﬁed
that the DIAPH1 FH1 domain interacts with the small
positively charged patch formed by Gln364, Arg365, Arg366,
and Gln367 on the RAGE cytoplasmic tail (Kd < 10 μM, Table
2).34
ERK. In vitro binding experiments by Ishihara and co-
workers conﬁrmed that the cytoplasmic tail bound both
phosphorylated and nonphosphorylated versions of ERK 1/2,
suggesting a direct interaction between the receptor’s intra-
cellular domain and the kinases.36 RAGE stabilizes ERK under
the membrane-proximal cytoplasmic region and leads to
activation of the interaction between ERK and other proteins.36
Consistent with these results, the HMGB1-induced kinase
activity of ERK is signiﬁcantly more pronounced in RAGE-
expressing cells.36 Similarly to DIAPH1, this demonstrates the
importance of simultaneous extracellular and intracellular
RAGE ligation for the activation of its subsequent downstream
pathways.34,36
PKCξ, TIRAP, and MyD88. A study by Sakaguchi et al.
endeavored to answer the question of whether DIAPH1 and
ERK are the only RAGE eﬀectors involved in facilitating RAGE
intracellular signaling pathways.33 In vitro experiments in
various cell lines conﬁrmed that the extracellular activation of
RAGE triggered the binding of protein kinase Cξ (PKCξ) to
the cytoplasmic domain, thereby resulting in RAGE phosphor-
ylation at Ser391.33 This process exhibited a dose-dependency
of the extracellular ligands, such as S100A11, S100A12,
HMGB1, and AGE, and was exclusive to RAGE, demonstrating
its potential involvement in inﬂammation, immune responses,
and other cellular functions.33
Phosphorylation at Ser391 inﬂuences the RAGE binding of
other intracellular eﬀectors, particularly TIRAP and myeloid
diﬀerentiation primary response gene 88 (MYD88).33 As
anticipated and in analogy to DIAPH1, this protein−protein
interaction produced an increase in the activity of downstream
RAGE signaling mediators such as NF-κB, JNK, Rac1, AKT,
Table 2. Extracellular Eﬀectors Binding to Cytoplasmic RAGE Domain
extracellular
eﬀectors RAGE isoform
aﬃnity for RAGE
(Kd) (μM) binding assay ref
DIAPH1a human RAGE <10 NMR 34
ERK 1/2 human and
mouse RAGE
in vitro binding, gel shifting assay, C-terminal truncation 36
PKCξ, TIRAP,
and MYD88
human RAGE in vitro binding, Western blotting, immunoprecipitation, kinase assay 33
DOCK7 human RAGE liquid chromatography and electrospray tandem mass spectrometry, Western blotting,
immunoprecipitation, in vitro cell migration and immunohistochemistry
89
aNMR structure of cytoplasmic RAGE domain in complex with DIAPH1 reported in ref 34.
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and p38.33 The inhibition of TIRAP, MYD88, or PKCξ activity
in endothelial cells resulted in a decreased production of
secondary RAGE eﬀector molecules, such as the epidermal
growth factors IL-1 and IL-6, which are involved in
inﬂammation and carcinogenesis.15,91 While the binding of
TIRAP and MYD88 by RAGE proved its similarity to the
aforementioned TLRs, Sakaguchi et al. showed the preference
of RAGE for these adaptor proteins over other TLR ligands.33
DOCK7. Employing immunoprecipitation and aﬃnity
puriﬁcation followed by mass spectrometry, it was discovered
that DOCK7 is an intracellular eﬀector of RAGE.89 As
expected, endogenous DOCK7 binds to RAGE but not to
DN-RAGE in HEK293T cells.89 DOCK7 is involved in the
activation of the GTPases such as Cdc42.89,92 The down-
regulation of DOCK7 resulted in marked interference with
signal transduction from RAGE to Cdc42, indicating the
involvement of DOCK7 in the RAGE-Cdc42 signaling axis in
human cancer cell lines.89
■ THE INVOLVEMENT OF RAGE IN DISEASE
PROCESSES
RAGE is expressed in vascular smooth muscle, mesangial,
endothelial, and lung alveolar epithelial cells, mononuclear
phagocytes, and neurons.11,93 Overexpression and activation of
full-length RAGE has been linked to neurodegenerative
disorders,5,8,9,50 diabetic nephropathy, and nondiabetic vascular
disease,12,94,95 acute liver and lung injuries,96−98 and malignant
tumors.15 The interaction of RAGE ligands with the
extracellular domain of RAGE initiates a downstream intra-
cellular cascade mediated through multiple mechanisms,
including the production of ROS and activation of ERK 1/2,
Janus kinase (JAK), transducer and activator of transcription
(STAT), Rho family of GTPases, MAPK, phosphatidylinositol
3-kinase (PI3K), AKT, and transcription factors (AP-1 and NF-
κB).9,17,37,48,49,51,99,100 Once activated, transcription factors
migrate into the nucleus, interact with the DNA and lead to
increased expression of pro-inﬂammatory cytokines, enzymes,
as well as oncogenes with associated downregulation of tumor
suppressor genes.101−103 In turn, this cascade generates
overexpression of RAGE and its ligands, such as AGEs,
S100B, and HMGB1, which leads to a positive feedback loop
and further RAGE upregulation.47−52
Tumorigenesis and Malignancy. In tumors, endothelial,
lymphocytic, myeloid, and myeloid-derived suppressor cells,
RAGE activation exerts gene upregulation and production of
S100 family proteins and inﬂammatory cytokines (e.g., TNF-α,
IL-1, and IL-6) via the NF-κB/AP-1 signaling cascade,
promoting angiogenesis (VEGF), tumor growth, and metastasis
(Figure 2).15,73,104 The stimulation of RAGE in colorectal
cancer cells by S100P proteins leads to NF-κB/AP-1 activation
through mitogen-activated protein kinase kinase (MEK), ERK
phosphorylation, and increased expression of oncogenes such
as microRNA-155.73,105 Antagonism of RAGE activity with
either the anti-RAGE antibody or the antagonist derived from
HMGB1 results in a pronounced reduction in cell growth,
migration, and invasiveness.73,105 The administration of
HMGB1 to human ﬁbrosarcoma cells overexpressing RAGE
activates Rho GTPases (Rac1 and Cdc420) and subsequently
transcription factors (NF-κB), exacerbating the malignant
cellular phenotype in vitro and in vivo.48
RAGE and the proinﬂammatory ligand S100A7 are co-
overexpressed in aggressive clinical breast cancer cases.16 RAGE
mediates S100A7-induced breast cancer growth and metastasis
by activation of ERK and transcription factors that induce the
expression of metalloproteinases (MMPs), enzymes involved in
angiogenesis and metastatic disease progression.16 In turn, the
Figure 2. Schematic representation of signaling pathways activated by RAGE in cancer, cardiovascular diseases, and neurodegeneration.
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F
administration of an anti-RAGE antibody or sRAGE to
S100A7-expressing transgenic mice inhibited further tumor
development and metastasis, whereas RAGE knockout mice
demonstrated lower activation of the ERK/NF-κB pathway.16
Diabetes and Cardiovascular Disease. RAGE and
expression of its proinﬂammatory ligands have been implicated
in chronic inﬂammation conditions such as atherosclerosis,
diabetic complications, and nondiabetic vascular disease (Figure
2).12,94,106 Increased expression of RAGE, vascular cell
adhesion protein 1, tissue factor, and MMPs has been
demonstrated in aorta and kidney of diabetic mice.94,106 The
activation of chronic inﬂammatory signaling pathways com-
promises vascular integrity and stimulates the clotting cascade
causing cardio- or renovascular damage.8,107 In diabetic rats
such eﬀects are exacerbated by AGE-induced cytosolic ROS
production that facilitates mitochondrial superoxide produc-
tion.108
RAGE and its ligands are implicated in the pathogenesis of
ischemia−reperfusion injury in the heart. In a murine model
subjected to myocardial ischemia, RAGE activity coincided with
enhanced expression of JNK or STAT5, the activators of the
NF-κB pathway.109 Pharmacological blockade of RAGE
Figure 3. Chemical structures of RAGE inhibitors. Inhibitors 1−11 have a common pharmacophore which comprises: (1) a central heteroaromatic
core capable of hydrogen bonding (green), (2) one or two hydrophobic regions (blue), and (3) a protonable nitrogen atom (red) connected to the
central core by an alkyl linker.
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activation with ursodeoxycholic acid exerts an antiatherogenic
activity in diabetic mice, whereas administration of sRAGE
protects them against ischemia−reperfusion injury.109−111
Neurodegeneration. Because numerous neurodegenera-
tive disorders, such as Alzheimer’s, Parkinson’s, Huntington’s
diseases, and amyotrophic lateral sclerosis, have been linked
with neuroinﬂammation, multiple research studies have
attempted to elucidate the role of RAGE physiology in their
development.9,112 Immunohistochemical studies with human
brain tissue have demonstrated that RAGE levels are increased
in AD patients versus controls.113,114 In AD patients, RAGE
expression is present on cerebral endothelial cells, astrocytes,
and neurons of the hippocampus, entorhinal cortex, and
superior frontal gyrus but absent in the cerebellum.113−116
In neurodegenerative disorders RAGE is implicated in the
amyloidogenic pathway as well as independent neurotoxic
immunoinﬂammatory cascades (Figure 2).8,9,45,82 The binding
of endogenous ligands, such as AGE, S100, or Aβ, to
physiologically expressed RAGE, leads to its overexpression
in neurons, microglia, astrocytes, and the vasculature of the
BBB.9,17,45,112,117
The increased presence of RAGE at the BBB leads to inﬂux
of Aβ and monocytes into the brain, whereas in neurons it
enhances the activity of the Aβ-producing β-secretase enzyme
(BACE1), induces tau hyperphosphorylation, neuroinﬂamma-
tion, and impairs neuronal function.17,84,117,118
Accumulation of Aβ1−40 and Aβ1−42 in the brain results in the
formation of oligomers and plaques inducing RAGE-mediated
apoptosis in neurons.9,17,25,45,82,119 In vitro microglial models
conﬁrmed that RAGE-S100B interaction leads to the activation
of the Rac-1/JNK axis and transcription factors (NF-κB and
AP-1).103 This increases in vivo hippocampal and cortical brain
production of BACE1 and the microglial/neuronal release of
inﬂammatory markers, such as TNF-α, IL-1, IL-6, and
chemokine (C−C motif) ligand 2 (CCL2).17,46,102
Because RAGE remains activated as long as Aβ peptide and
Aβ oligomers are present, RAGE may be involved in initiation
and ampliﬁcation of Aβ neuronal toxicity.82 Takuma et al.
demonstrated that RAGE also contributes to the translocation
of Aβ1−40 from the extracellular to the intracellular space,
spreading among the cells and causing neuronal damage.120 As
expected, the inhibition of RAGE activity shows a pronounced
drop in both in vitro and in vivo levels of brain ROS as well as
improved cognitive function in animals and AD patients.17,46,121
■ DEVELOPMENT OF RAGE INHIBITORS 1−19:
BINDING TO THE EXTRACELLULAR DOMAIN
This section considers RAGE as a therapeutic target and
discusses synthetic small-molecule inhibitors that have been
developed to date.
The [3-(4-{2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1H-imi-
dazole-4-yl}-phenoxy)-propyl]-diethylamine 1 (azeliragon, also
called PF-04494700 or TTP488, Figure 3, Table 3) is an orally
bioavailable small molecule able to cross the BBB.19,121,122 1
inhibits the interaction between RAGE and Aβ1−42, S100B,
HMGB1, and CML. 1 also inhibits the binding of sRAGE to
Aβ1−42 (IC50 ∼ 500 nM) determined by a ﬂuorescent
polarization assay.19,121,122
In AD plaque-developing transgenic mice, the administration
of 1 (ip 10 mg/kg per day or po 20 mg/kg per day) caused a
signiﬁcant reduction in inﬂammatory markers (TNF-α, TGF-β,
and IL-1), CNS amyloid deposition and improvement of
cognitive functions.19 1 reduced accumulation of Aβ peptides in
the spleen and the expression of IL-6 and macrophage colony
stimulating factor in a mouse model of systemic amyloidosis.122
The safety and eﬃcacy of 1 has been investigated in humans
(phase I and II clinical trials).19,121,122 In the double-blind
phase IIa trial, mild-to-moderate AD patients were treated
orally with high dose of 1 (27 patients with 60 mg/day for 6
days then 20 mg daily for up to 10 weeks), low dose (28
patients with 30 mg/day for 6 days then 10 mg daily for up to
10 weeks), or placebo (12 patients). The doses appeared to be
safe and well tolerated, but treatment did not show any
diﬀerences in plasma Aβ levels, inﬂammatory biomarkers, or
cognitive measures.122 A larger multicenter study involving 399
AD patients (phase II trial, NCT00566397) was carried out to
determine if there was any evidence of 1’s eﬃcacy in slowing
down cognitive decline: 135 patients were assigned to a high
dose of 1 (60 mg/day for 6 days followed by 20 mg/day for up
to 6 months), 135 patients to a lower dose (20 mg/day for 6
days followed by 5 mg/day for up to 18 months), and 132
participants to placebo.19 The high dose treatment was
discontinued at 6 months due to confusion, falls, and signiﬁcant
worsening in cognitive measures (no changes to CSF and
plasma levels of Aβ were observed). The accelerated cognitive
decline slowed post treatment.19 In contrast, patients treated
with the lower dose showed a beneﬁcial eﬀect against cognitive
decline.121 The phase III clinical trial of RAGE inhibitor 1 is
currently in progress in a mild AD cohort (2015−2018,
NCT02080364, Clinicaltrial.gov).
The structure of 1 presents two hydrophobic moieties, an
aliphatic chain and an electron deﬁcient aromatic group,
attached to a heteroaromatic central core (Figure 3). The
central core is linked to an alkyl chain containing a protonable
nitrogen. By substituting the imidazole ring with a thiazole, a
library of RAGE antagonists was synthesized and evaluated,
leading to the discovery of the trisubstituted thiazole 2 (Figure
3, Table 3) able to inhibit the RAGE-Aβ1−42 interaction (IC50 =
1.21 μM).123 Structure−activity relationship (SAR) studies
revealed that the aminoalkiloxy linker is essential for RAGE
inhibition, and no signiﬁcant diﬀerences in inhibitory activity
are observed by modifying the thiazole ring or by inserting an
amide or an amino group between the thiazole and the 4-
chlorophenoxyphenyl. Using an artiﬁcial BBB system, 2 showed
Aβ transport inhibition using a RAGE-overexpressing brain
endothelial cells monolayer.123
Similarities with the pharmacophore of 1,2 are observed in a
new class of 4,6-diaryl 2-aminopyrimidines (3−6, Figure 3),
which exhibited good inhibitory activities against RAGE-Aβ
interaction in an enzyme-linked immunosorbent assay (ELISA,
IC50 values <20 μM).
124−126 Inhibitors 3−6 comprise two
aromatic groups (4-halophenyl ring), a pyrimidine central core
and an alkyl chain containing a protonable nitrogen. SPR
showed that 3 directly binds to RAGE (Kd = 102 μM).
124 The
binding mode of 3 to the RAGE V domain was evaluated
through a ﬂexible computational docking study, showing that 3
forms a net of hydrogen bonds between: (a) the oxygen atom
of the ethoxy linker and Arg48, (b) two nitrogen atoms of the
pyrimidine core and Arg104, and (c) the terminal amine and
Met102.124 Moreover, the two electronegative 4-chlorophenyl
rings interact with a positively charged area rich in Lys and Arg
residues.124 In vitro studies showed that 3 (10 μM) causes a
down-regulation of Aβ-induced NF-κB signaling in C6 glioma
cells.124 However, 3 exhibited high toxicity when administered
to hippocampal neuronal cells (HT22) at 10 μM (cell survival:
37.3%).125 In vivo studies in wild-type mice showed that 3
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injected (ip) prior to human Aβ administration inhibited Aβ
brain entry via RAGE at the BBB.124 Oral administration of 3
(50 mg/kg per day for up to three months) to APPswe/PS1
mice signiﬁcantly lowered the concentration of toxic soluble Aβ
in the brain and improved cognitive function.124 Again, SAR
studies highlighted that the N-aryl linker is crucial for RAGE
inhibition, and its modiﬁcation might lead to loss of biological
activity.
Modiﬁcations on the position of the N,N-diethylamino linker
of the aromatic ring led to improvements in potency of 2-
aminopyrimidine derivative 4 (IC50 = 4.6 μM).
124 Further
modiﬁcations to the terminal tertiary amine unit and linker
length led to the discovery of 5 (Figure 3). The ﬂexibility of the
N,N-diethylamino linker in 5 is restricted by using a pyrrolidine
ring. 5 showed improved RAGE-Aβ1−42 inhibition and solubility
compared to 3.126 The binding mode, predicted by molecular
docking, of 5 is similar to 3, however, additional hydrogen
bonds are predicted to occur between Arg48 and the nitrogen
atom of the pyrrolidine ring. In addition, the dimethylamino
group attached to the pyrrolidine ring lies in a relatively
hydrophobic section consisting of Met102 and Gly106.126
Hence, a pyrimidine-2-carboxamide analogue 6 (Figure 3)
was designed by replacing the chlorine with ﬂuorine atom and
by inserting an amide group in the central core.125 6 showed
low cytotoxicity (100.4 ± 3.2% of cell viability with HT22 cells)
and superior RAGE inhibition than 3 at 20 μM (ELISA
assay).125
By substituting the pyrimidine ring of 6 with a pyrazole ring,
Han et al. synthesized a library pyrazole-5-carboxamide
derivatives.127 Among them, 7 (Figure 3), containing a
ﬂuorobenzene, a butoxy substituent, and the essential N,N-
(diethyl)phenoxyalkylamine moiety, showed better RAGE
inhibitory activity (IC50 = 1.9 μM, ELISA) than 3 (IC50 =
16.5 μM).127 SPR assays conﬁrmed their direct binding to
RAGE (Kd (7) = 43.4 μM, Kd (3) = 102 μM).
127 Analogues of
7 that do not contain the butoxy substituent maintained good
RAGE inhibitor activity. Molecular docking analysis of 7 using
the RAGE V domain suggested that the 4-ﬂuorophenyl moiety
might ﬁt into an electropositive groove formed by Lys107.127
Undesired cytotoxicity was observed in HT22 cells at 10 μM
(cell survival: 10.3%).125 In vivo studies of 7 (iv 25 mg/kg) in
wild-type mice prior to iv human Aβ administration showed
that 7 is able to reduce Aβ entry in the brain.127
A series of benzoxazole analogues reported by Lee et al. have
a similar pharmacophore: an electron deﬁcient aromatic group,
a heteroaromatic central core, and a linker containing a
protonable nitrogen.
The interaction between RAGE and Aβ was measured by a
ﬂuorescence resonance energy transfer (FRET) assay on mouse
HT22 cells using RAGE-cyanine dye and Aβ-ﬂuorescein. The
reduction of the FRET signal induced by a library of
benzoxazole analogues (4 μM) was recorded and calculated
as percentage of inhibition. A 6-phenoxy-2-phenylbenzoxazole
derivative 8 (Figure 3) inhibited the RAGE-Aβ interaction in
vitro (65%) and was not toxic in HT22 cells at 10 μM.128 SAR
studies demonstrated how the substitution of the chloride on
the electron deﬁcient aromatic group with a ﬂuorine or CF3 did
not improve the activity. Instead, compounds with a long and
ﬂexible linker showed good RAGE inhibition.128 Modiﬁcation
of the basicity of the nitrogen atom was deleterious to
biological activity.128 Administration of 8 (po 50 mg/kg every 2
days for 4 weeks) to transgenic APPswe/PS1 mice (34 weeks
old) blocked the transport of peripheral Aβ1−40 into the brain
but did not signiﬁcantly aﬀect Aβ and amyloid plaque levels in
the brain.128
Compounds 9−11 (Figure 3), having similar chemical
features to 1−8, were able to inhibit the interaction of
sRAGE to S110B (IC50 of 1.75, <0.5, and <0.5 μM,
respectively), amyloid β (3.4, <0.5, and <0.5 μM, respectively)
and CML (2.29, <0.5, and <0.5 μM, respectively).129−132
N-Benzyl-N-cyclohexyl-4-chlorobenzamide 12 (FPS-ZM1,
Figure 4) was selected through screening 5000 compounds in
the search for RAGE inhibitors.17 12 appeared to block the
interaction between Aβ1−40 and Aβ1−42 and RAGE V domain in
vitro and in vivo.17 Using a cell-free assay with immobilized
sRAGE, 12 blocked RAGE binding to Aβ (Ki = 25 nM), S100B
(Ki = 230 nM), and HMGB1 (Ki = 148 nM) and did not bind
to immobilized Aβ.17 The SAR of 12 revealed that the features
associated with RAGE binding are (1) a tertiary amide central
core, (2) an electron deﬁcient benzene, (3) a hydrophobic
moiety, and (4) an electron-rich benzene ring linked to the
amide with an alkyl spacer.133 The binding mode of 13 (Figure
4), a ﬂuorine analogue of 12, to the RAGE V domain was
predicted by molecular docking studies.18 This binding
appeared to be largely dependent on hydrophobic interactions
with Pro45, Leu49, Trp51, Pro66, Leu78, and Pro80.18
In a receptor-binding assay using RAGE-transfected Chinese
hamster ovary (CHO) cells, 12 inhibited the RAGE-Aβ
interaction with a Ki of 25 nM.
17 In RAGE-transfected CHO
cells, 12 was nontoxic at 10 μM and reduced RAGE-mediated
cellular oxidative stress, BACE1 mRNA, BACE1 activity
(induced by Aβ1−40 and Aβ1−42), and nuclear NF-κB levels
(induced by Aβ1−40).
17
In 15−17-month-old APPsw/0 mice, 12 was not toxic up to
500 mg/kg (ip) and inhibited RAGE-mediated inﬂux of
circulating Aβ1−40 and Aβ1−42 into the brain at the luminal
side of BBB, reducing their levels in the cortex and the
hippocampus. Furthermore, 12 bound exclusively to RAGE in
the CNS. The treatment with 12 (ip 1 mg/kg daily for 2
months) also reduced soluble APP β protein, p65, NF-κB, and
Figure 4. Structures of 12−14 and radiosynthesis of [18F]13.
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BACE1 mRNA levels in the cortex and the hippocampus. As a
result, 12 reduced Aβ-induced RAGE-dependent oxidative
stress in neurons, suppressed microglia activation, and
neuroinﬂammation as well as normalized cerebral blood ﬂow
and cognitive performance.17
A RAGE-AGEs rat model, activated by intrahippocampal
injection of AGEs, treated with 12 (ip 1 mg/kg/day for 4
weeks), showed a reduction of: (1) expression of Aβ and
amyloid precursor protein (APP) production, (2) NF-κB-
mediated Aβ production, (3) inﬂammatory response in the
cortex and hippocampus, and (4) ROS and lipid peroxidation
along with an increased antioxidant enzyme activity.46 In the
aortas of aged rats, 12 reduced malondialdehyde and ROS
production and increased GSH/GSSG ratio.134
Fluorine-18 radiolabeled 13 ([18F]13, Figure 4) was
developed for use in positron emission tomography (PET)
imaging in vivo.18 [18F]13 was obtained using a trimethylam-
monium precursor and [18F]ﬂuoride in the presence of
Kryptoﬁx-2.2.2 (K2.2.2) in DMF at 130 °C for 30 min.18 In
vitro autoradiography of human brain tissue showed higher
uptake of [18F]13 in the frontal cortex of AD compared with
healthy control tissue. However, when studied in vivo,
signiﬁcant nonspeciﬁc binding to the white matter was
observed, peaking within 3 min post iv injection and followed
by virtually complete washout over the duration of the PET
scan. [18F]13 was rapidly metabolized in rat liver microsomes.18
The RAGE inhibitor 14 (matrine, Figure 4) was identiﬁed by
high-throughput screening of the main components of Chinese
traditional medicinal herbs.135 14 suppressed the Aβ-mediated
RAGE signaling pathway in vitro and in vivo. However,
microscale thermophoresis studies revealed a weak interaction
between 14 and RAGE. Docking simulations proposed that 14
interacts with V domain through hydrogen bonding and a
hydrophobic interaction with Ile26, Leu34, Val35, Leu36, and
Lys37.135 Aggregation studies using ThT ﬂuorescence and
TEM microscopy showed that 14 (50 μM) prevents Aβ
aggregation or ﬁbrillation. In RAGE-overexpressing neuro-
blastoma cell lines, 14 (50 μM) inhibits the Aβ1−42 aggregation
and suppresses the RAGE-Aβ signaling pathway, as demon-
strated by the decrease of NF-κB and BACE1 expression levels.
In AD transgenic mice model studies, 14 (ip 100 mg/kg) is
transported across the BBB, reduces brain Aβ, NF-κB, BACE1
levels, and downregulates proinﬂammatory cytokines (TNF-α
and IL-1β) as well as attenuates memory deﬁcits.135
Glycosaminoglycans 15 (chondroitin sulfate E, Figure 5), 16
(heparan sulfate), and 17 (heparin) have a high aﬃnity for
RAGE (Kd = 0.2, 0.6, and 3.1 nM, respectively).
136,137 A single
preadministration of 15 or 16 suppressed the colonization of
the lungs by cancer cells.136,137 The antagonistic eﬀect of 17
against RAGE inhibited tumor cell growth, migration, invasion,
and distant metastasis in vitro and in vivo.48 A non-
anticoagulant semisynthetic glycosaminoglycan ether with an
average molecular weight of 5.5 kDa 18 (GM-1111, Figure 5)
exhibited a RAGE binding aﬃnity of 1.69 nM.137 18 inhibited
the interaction of RAGE with CML, S100B, and HMGB-1 with
IC50 values of 413, 275, and 80 nM, respectively. The acidic
anionic and alkyl groups of 18 are likely to interact with the V
domain containing hydrophobic and basic amino acids.137
Furthermore, 18 displayed a substantial anti-inﬂammatory
activity at nanomolar concentrations.137
Two studies on RAGE antagonistic peptides have been
reported so far. Peptide 19 (ELKVLMEKEL, Figure 5),
developed from the structure of S100P, competes for a site
on RAGE that is required for receptor binding by S100P,
S100A4, and HMGB.138 19 reduced RAGE activation of NF-
κB, inﬂammation, tumor growth, and metastasis in several
cancer cell lines. Using immune-deﬁcient mice implanted with
cancer cells, ip delivery of 19 caused a reduction of tumor
growth, metastasis, and inﬂammation.138 Peptides derived from
the carboxy-terminal region of HMGB1 (150−183, 162−177,
and 160−183) bind to RAGE and eﬃciently inhibit RAGE−
HMGB1 mediated invasive migration of tumor cells both in
vitro and in vivo.63
Figure 5. Structures of glycosaminoglycans (15 and 18) and the small peptide 19.
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■ RAGE INHIBITORS BINDING TO THE
INTRACELLULAR RAGE DOMAIN (20−28)
A novel mechanism for speciﬁc inhibition of RAGE signaling
has been proposed by using inhibitors targeting the cytoplasmic
domain of RAGE interfering with the RAGE−DIAPH1
interaction. A library of 58000 small molecules were evaluated
by a high throughput RAGE−DIAPH1 binding assay.35
Fluorescence titration experiments and NMR spectroscopy
demonstrated that compounds 20−28 (Figure 6, Table 3)
exhibited nM aﬃnity (Kd = 0.3−32 nM) to the cytoplasmic
domain of RAGE responsible for RAGE−DIAPH1 interac-
tion.35,139
20−25 present a common pharmacophore, which can be
divided in three diﬀerent moieties: (1) a hydrophobic aromatic
or aliphatic moiety (in black), (2) a central group that may
form hydrogen bonds (in red), and (3) a substituted aromatic/
heteroaromatic moiety (in blue). The other set of compounds
26−28 contain a hydrophobic tricyclic ring and a benzimida-
zole connected by an alkyl chain bearing an hydroxyl group,
thereby ensuring the possibility of donating and accepting
hydrogen bonds. NMR spectroscopy demonstrated that 20−28
interact with the cytoplasmic domain of RAGE by forming
hydrogen bonds with Gln364 and Gln367 and a cation−π
interaction with Arg365 and Arg366.34 However, the binding
sites of compounds 20−25 and 26−28 may not completely
overlap.34
In vitro RAGE−DIAPH1 competitive inhibitors displayed
inhibitory eﬀects on RAGE−CML signal transduction, vascular
cell migration, and pro-inﬂammatory cytokines. In vivo RAGE−
DIAPH1 inhibitors decreased inﬂammation caused by CML or
methylated bovine serum albumin on wild-type mice.35,139
■ FUTURE PERSPECTIVE AND CONCLUSIONS
This perspective reviews the state-of-the-art regarding: (1) the
endogenous intracellular RAGE ligands and extracellular
eﬀectors, and biochemical pathways modulated by the
activation of RAGE, (2) the small molecule RAGE inhibitors
and SAR generated to date, and (3) the use of RAGE inhibitors
for potential treatment of cancer, cardiovascular diseases, and
neurodegeneration.
Well-deﬁned binding models have been developed for many
RAGE−ligand interactions (AGEs, S100A6, S100B, S100P, and
DIAPH1), however, relatively little is known about the binding
sites of quinolinic acid, HMGB1, S100A12, Aβ, or intracellular
eﬀector proteins, including TIRAP, ERK, PKCξ, and
DOCK7.22,24,28,34,62,72,83,87,140
All studies investigating the binding of RAGE to its
intracellular eﬀector proteins have employed diﬀerent cell
lines and have not unequivocally established the phosphor-
ylation status of Ser391 upon ligand binding to the extracellular
domain, hampering a clear interpretation of data ob-
tained.33−36,89 While TIRAP requires phosphorylation of
RAGE for its interaction, ERK binds to both phosphorylated
and unphosphorylated RAGE.33,36 The signiﬁcance of the
phosphorylation status of other intracellular eﬀectors is still
unknown. The question of whether or not simultaneous
binding of multiple ligands/eﬀectors to RAGE is required to
initiate the downstream signaling also remains unanswered.
Further crystallography, NMR, and computational studies are
required to clarify precise binding mechanisms of intracellular
eﬀectors to the cytoplasmic RAGE domain.
Some of the mechanistic questions posed above may be
addressed by exploring the changes in the expression of
signaling genes (e.g., JNK, AKT, Cdc42, NF-κB) following the
inhibition of each extracellular or intracellular RAGE−ligand
interaction in diﬀerent cellular models. This may not only lead
to improved understanding of diﬀerences in RAGE signaling
pathways in each disease state (potentially identifying new
molecular targets) but would also help design more disease-
speciﬁc inhibitors.
Figure 6. Small organic molecules binding the cytoplasmic domain of RAGE.
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Another variable to consider is the degree of RAGE
oligomerization.21,23,28−30 Small molecules which inhibit/
stabilize this process may prove eﬀective by reducing the
RAGE−ligand interaction and preventing the downstream
eﬀects (e.g., activation of intracellular eﬀectors, GTPase, or
kinase-mediated pathways).
All truncated isoforms of RAGE (sRAGE, DN-RAGE, N-
RAGE) occur naturally in tissues but do not trigger intracellular
downstream signaling. Among them, sRAGE has been
investigated as a disease biomarker and scavenger of excessive
AGE, S100, HMGB1, or Aβ, thus decreasing their accumulation
at the site of organ damage.11,13,14,56 Similarly, small molecules
which enhance the level of truncated isoforms of RAGE at the
expense of full-length RAGE may act as modulators of RAGE-
mediated pathophysiological processes.
This review highlights a number of chemical entities that
block RAGE activation by binding to the extracellular or
intracellular domains.
Potent and selective inhibitors of RAGE (1−19) binding to
three regions of V domain have been discovered and developed.
Compounds 1−11 were found to possess activity in cell-based
assays and in AD animal models, with the most advanced
compound 1 undergoing clinical trials in patients with mild
AD.19,122−127 These compounds share a common pharmaco-
phore: one or two hydrophobic aromatic rings, a central core
with hydrogen bond acceptor/donor atoms, and a alkyl linker
bearing a protonable amine. It has been proposed by docking
simulation that they interact with a pocket consisting of Lys43,
Lys44, Arg48, Met102, and Arg104 (Figure 7).
The RAGE-speciﬁc inhibitor 12 has the ability to disrupt
RAGE−Aβ1−40 interactions, exhibits acceptable BBB perme-
ability, and has a good toxicology proﬁle in cell culture and
rodents.17,46 Compound 12 also reduces amyloid-β-mediated
brain dysfunction in murine models of AD.17,46 12 was used as
a chemotype for development of the potential PET radiotracer
([18F]13) with the aim to quantify CNS RAGE in vivo.18
Further in vivo characterization of this radiotracer will be
required to demonstrate the potential utility of [18F]13.
Molecular docking studies of RAGE protein conﬁrmed that
the interaction of 12,13 with its conserved residues (Leu49 and
Trp51, Figure 7) is important for the RAGE−Aβ interaction.140
Compound 14 inhibits Aβ-induced cytotoxicity and
suppresses the RAGE−Aβ signaling pathway in vitro and in
vivo.135 14 reduces proinﬂammatory cytokines and Aβ
deposition, attenuating the memory deﬁcits of AD transgenic
mice.135 Molecular docking analysis of 14 demonstrated its
binding pattern to the V domain through hydrophobic
interactions with Val35, Leu36, and Ile26 as well as hydrogen
bonds with Lys37 (Figure 7).135 However, the three binding
regions of 1−14 involved in the interaction with RAGE have
been proposed solely based on molecular docking simulations
(Figure 7). Therefore, the elucidation of structures of RAGE−
inhibitor complexes by X-ray or NMR should conﬁrm the
proposed binding mode and provide useful tools for future
design of more stable and/or potent inhibitors. By binding to
the extracellular domain of RAGE, glycosaminoglycans (15−
18)136,137 and the small peptide (19)138 inhibited tumor cell
growth, migration, invasion, and metastasis in vitro and in vivo.
Manigrasso et al. identiﬁed 20−28 as potent RAGE
inhibitors binding to the intracellular domain (Figure 7).
They exhibit in vitro and in vivo inhibition of RAGE-dependent
molecular processes.35 NMR spectroscopy studies demonstra-
ted that 20−28 interacted directly with the domain involved in
the DIAPH1 interaction. This domain is not present in the
truncated isoforms of RAGE (sRAGE and DN-RAGE), and
therefore oﬀers great promise for the future development of
RAGE inhibitors speciﬁc for the full length RAGE.
The intracellular (1−19) and extracellular (20−28) inhib-
itors discussed above may act as scaﬀolds for further chemical
reﬁnement and optimization tailoring their activity, selectivity,
and pharmacokinetics and leading to future success in the
development of in vivo imaging radiotracers. Such tracers
Figure 7. A cartoon of the V domain structure of the human RAGE with putative binding sites of 1−14 (dashed lines) is depicted. 1−19 bind to the
V domain and 20−28 to the cytoplasmic region.
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would help elucidate the changes of in vivo RAGE expression
and distribution in both normophysiological and pathological
conditions.
The results obtained by in vitro and in vivo studies of 1−28
conﬁrmed how RAGE inhibition could be a powerful tool for
the management of immunoinﬂammatory pathologies. Inde-
pendent of the physiological model used, the inhibition of
RAGE resulted in a normalized inﬂammatory response as
evidenced by the reduction in NF-κB activation, cytokine
production, and RAGE expression. Given the crucial role of
RAGE in many diseases, it is anticipated that these initial
chemical scaﬀolds will prime RAGE drug discovery programs in
the ﬁeld of neurodegeneration, tumorigenesis, and vascular
disease. The diversity of RAGE signaling, activated through the
binding of various ligands and eﬀectors, suggests that future
research should consider the aﬃnity of RAGE inhibitors for
diﬀerent RAGE domains, oligomers, and isoforms. In addition,
compounds targeting downstream proteins could provide a
desired synergistic eﬀect once combined with a RAGE
inhibitor. The existing RAGE-speciﬁc molecules may serve as
useful scaﬀolds for future ligand-based development and
optimization of novel drug candidates targeting RAGE. Further
developments in the characterization of 3D RAGE−inhibitor
complexes will be crucial for the generation of new RAGE
chemotypes and “drug-like” molecules using a structure-based
drug design approach. Given the emerging importance of this
target in multiple diseases, future developments in RAGE
medicinal chemistry presents fertile ground for the develop-
ment of a new generation of novel therapeutics.
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Díaz-Garrido, P.; Loṕez-Macay, A.; Martínez-Flores, K.; Loṕez-Reyes,
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